Macomics, an Edinburgh, Scotland & Cambridge, UK-based immuno-oncology company, raised £4.24M in funding.
The round, which brought total funding raised to date to £7.44m, was led by Epidarex Capital with participation from new investor Caribou Property Limited and Scottish Enterprise.
The company intends to use the funds to expand:
- its macrophage-based therapeutics R&D portfolio,
- its facilities in Edinburgh and Cambridge, and
- its scientific team to support its accelerated R&D.
Co-founded in 2019 by Prof Jeffrey Pollard and Dr Luca Cassetta, now VP Immunology, and led by Dr Steve Myatt, Chief Executive Officer, and Dr Carola Ries, Chief Scientific Officer, Macomics provides immuno-oncology expertise in macrophage biology, developing precision medicines to modulate macrophages for the treatment of cancer. The company is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic. Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.